However, SAS and HSC-2 tumor volume reduction on day 23 by 13-mG2a-f treatment only reached 51% and 57%, respectively, indicating that anti-PD-L1 therapy might not be sufficient for solo treatment of most oral cancers. This evidence concerns the gene CD274 and neoplasm.